http://www.xconomy.com/san-diego/2009/07/23/no-more-tears-avanir-investors-await-trial-results-on-emotional-outburst-drug/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 03:54:18 +0000 hourly 1 http://wordpress.org/?v=3.0.4 http://www.xconomy.com/san-diego/2009/07/23/no-more-tears-avanir-investors-await-trial-results-on-emotional-outburst-drug/comment-page-1/#comment-71943 Dr. Anwar Thu, 23 Jul 2009 23:17:34 +0000 http://www.xconomy.com/?p=34781#comment-71943 Ms. Gellene should be commended for a terrific review of this company and the history of Zenvia's development. Despite being long the stock and having followed the company for several years, I learned new information from this article. While the market for PBA is modest to large, the market for diabetic neuropathic pain is much larger. In my opinion as a cardiologist, the cardiac risk of QT prolongation has been essentially eliminated with the lower dose of quinidine. The questions are: A. "will the drug be effective for PBA and in the future for diabetic neuropathy?", B. "how is the side effect profile, or how is the drug tolerated by patients?". If the answer is yes, then the drug will generate multi-hundred million to billion (plus) dollars in sales. Ms. Gellene should be commended for a terrific review of this company and the history of Zenvia’s development. Despite being long the stock and having followed the company for several years, I learned new information from this article.
While the market for PBA is modest to large, the market for diabetic neuropathic pain is much larger. In my opinion as a cardiologist, the cardiac risk of QT prolongation has been essentially eliminated with the lower dose of quinidine. The questions are: A. “will the drug be effective for PBA and in the future for diabetic neuropathy?”, B. “how is the side effect profile, or how is the drug tolerated by patients?”. If the answer is yes, then the drug will generate multi-hundred million to billion (plus) dollars in sales.

]]>